Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stock Holdings Increased by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. boosted its holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 80.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 212,246 shares of the company's stock after buying an additional 94,651 shares during the period. Hennion & Walsh Asset Management Inc. owned 0.37% of Olema Pharmaceuticals worth $1,237,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Victory Capital Management Inc. raised its position in shares of Olema Pharmaceuticals by 9.9% in the 3rd quarter. Victory Capital Management Inc. now owns 851,512 shares of the company's stock worth $10,167,000 after buying an additional 76,720 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Olema Pharmaceuticals by 168.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 330,761 shares of the company's stock valued at $3,949,000 after purchasing an additional 207,565 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Olema Pharmaceuticals by 10.8% during the 3rd quarter. Wellington Management Group LLP now owns 1,002,685 shares of the company's stock worth $11,972,000 after purchasing an additional 97,428 shares during the period. Point72 Asset Management L.P. acquired a new stake in Olema Pharmaceuticals during the 2nd quarter worth approximately $34,753,000. Finally, Barclays PLC raised its holdings in Olema Pharmaceuticals by 105.0% in the third quarter. Barclays PLC now owns 94,915 shares of the company's stock valued at $1,133,000 after buying an additional 48,614 shares during the period. Hedge funds and other institutional investors own 91.78% of the company's stock.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Olema Pharmaceuticals in a research report on Wednesday, December 11th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $27.00.

Insider Activity

In other news, insider David C. Myles sold 12,452 shares of Olema Pharmaceuticals stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $9.38, for a total value of $116,799.76. Following the transaction, the insider now owns 611,947 shares of the company's stock, valued at $5,740,062.86. The trade was a 1.99 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Bain Capital Life Sciences Inv purchased 300,000 shares of the company's stock in a transaction on Wednesday, January 8th. The stock was bought at an average cost of $5.76 per share, for a total transaction of $1,728,000.00. Following the acquisition, the insider now directly owns 7,800,000 shares of the company's stock, valued at $44,928,000. This represents a 4.00 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 773,797 shares of company stock valued at $5,414,609. Company insiders own 19.40% of the company's stock.

Olema Pharmaceuticals Trading Up 7.2 %

NASDAQ:OLMA traded up $0.38 during mid-day trading on Friday, hitting $5.66. The stock had a trading volume of 1,698,873 shares, compared to its average volume of 1,193,573. The company has a 50 day simple moving average of $7.65 and a 200-day simple moving average of $10.81. Olema Pharmaceuticals, Inc. has a 52 week low of $4.60 and a 52 week high of $16.77. The stock has a market capitalization of $324.32 million, a price-to-earnings ratio of -2.58 and a beta of 2.05.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.